Lupin Share Price
07 Aug, 2026 1:09 PM (IST)
Lupin Performance
- Today's Low
- ₹2,368
- Today's High
- ₹2,410
- 52 Week Low
- ₹1,855
- 52 Week High
- ₹2,530
- Open Price₹2,410
- Previous Close₹2,385
- Volume1,460,284
- 50 DMA₹2,389.90
- 100 DMA₹2,339.60
- 200 DMA₹2,255.00
Lupin Chart
Investment Returns
- Over 1 Month -4.62%
- Over 3 Month -2.72%
- Over 6 Month + 9.33%
- Over 1 Year + 28.33%
Smart Investing Starts Here Start SIP with Lupin for Steady Growth!
Lupin Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 19.7
- PEG Ratio
- 0.4
- Market Cap Cr
- 108,662
- P/B Ratio
- 4.8
- Average True Range
- 52.7
- EPS
- 120.9
- Dividend Yield
- 0.8
- MACD Signal
- -2.2
- RSI
- 45.83
- MFI
- 45.43
Latest Stock News Updates
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Lupin announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423="">Total Revenue from operations in Q1FY27 reached Rs 82,768.9 million, reflecting a YoY growth of 32.04% compared to Rs 62,683.4 million in Q1/FY26 and a QoQ increase of 10.73% from Rs 74,746.6 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Total income for the group stood at Rs 84,072.1 million in Q1FY27, up 32.45% YoY from Rs 63,473.8 million in Q1FY26 and 10.40% higher QoQ than Rs 76,153.7 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Profit before tax and exceptional items in Q1FY27 was Rs 20,173.6 million, an increase of 42.51% YoY over Rs 14,155.4 million in Q1FY26 and a 4.63% growth QoQ compared to Rs 19,280.0 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Net Profit after tax for Q1FY27 was Rs 14,169.8 million, marking a YoY growth of 16.01% from Rs 12,214.6 million in Q1FY26, while declining 3.52% QoQ from Rs 14,686.7 million in Q4FY26.</li> </ul> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423="">Total Revenue from operations in Q1FY27 was Rs 71,719.0 million, representing a YoY increase of 25.63% from Rs 57,085.9 million in Q1FY26 and a QoQ increase of 37.01% from Rs 52,346.0 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Total income in Q1FY27 stood at Rs 72,743.8 million, growing 26.23% YoY from Rs 57,627.3 million in Q1FY26 and 36.65% QoQ from Rs 53,234.3 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Profit before tax for Q1FY27 was Rs 36,100.6 million, an increase of 39.48% YoY from Rs 25,881.5 million in Q1FY26 and a 38.72% QoQ increase from Rs 26,023.5 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">Net Profit after tax reached Rs 27,146.0 million in Q1FY27, reflecting a YoY growth of 27.56% from Rs 21,280.7 million in Q1FY26 and a 25.46% QoQ growth from Rs 21,636.9 million in Q4FY26.</li> <li _ngcontent-ng-c2478508423="">The standalone profit for Q1FY27 includes a reversal of provision amounting to Rs 4,493.9 million (USD 50.0 million) related to Generic Pharmaceuticals Antitrust Litigation, which was recorded by a subsidiary.</li> </ul> <p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Segment Performance:</strong> <ul> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Pharmaceuticals:</strong> Revenue from operations in Q1FY27 was Rs 82,343.5 million compared to Rs 62,364.1 million in Q1FY26. Segment results (profit) for the quarter stood at Rs 20,605.6 million.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Others:</strong> Revenue from operations was Rs 430.3 million in Q1FY27 compared to Rs 322.8 million in Q1FY26. Segment results for the quarter showed a loss of Rs 432.0 million.</li> </ul> </li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Acquisitions:</strong> On April 01, 2026, the company, through its subsidiary, concluded the acquisition of VISUfarma B.V., Netherlands, for a total consideration of Rs 20,902.7 million (Euro 192.8 million).</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Arbitration Award:</strong> During Q1FY27, the Group received an arbitration award and consequently accounted for an income of Rs 603.2 million (USD 6.9 million).</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Litigation Settlement:</strong> In April 2026, a wholly owned subsidiary settled an ongoing litigation dispute for an amount of Rs 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing.</li> <li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">ESOP Allotment:</strong> During Q1FY27, the company allotted 53,425 equity shares of Rs 2/- each under ESOP plans, resulting in an increase of paid-up equity share capital by Rs 0.1 million.</li> </ul> <p><strong>Nilesh Gupta, Managing Director, Lupin, said:</strong> “We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability. Our focus on execution, operational excellence, and sustained investments in technology and innovation continue to strengthen the business and position us for sustainable, profitable growth over the long term”.</p> <p><a class="lb" href="/get-document/post/pdf/5770611/" target="_blank">Result PDF</a></p>
- Trendlyne
- 20 minutes 36 seconds ago
Investor Presentation (Revised) - Q1 FY27 Results
- BSE India
- 11 hours 52 minutes ago
Investor Presentation- Q1 FY2027
- BSE India
- 14 hours 56 minutes ago
Lupin Financials
Lupin Technicals
EMA & SMA
- Bearish Moving Average 11
- Bullish Moving Average 5
- 20 Day
- ₹2,415.50
- 50 Day
- ₹2,389.90
- 100 Day
- ₹2,339.60
- 200 Day
- ₹2,255.00
Resistance and Support
- R3 2,459.40
- R2 2,443.50
- R1 2,414.30
- S1 2,369.20
- S2 2,353.30
- S3 2,324.10
Lupin Corporate Actions - Bonus, Splits, Dividends
Lupin F&O
About Lupin
Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices.
Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio.
Business Verticals
1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs
Company History
Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.
Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs.
Milestones
1968 - Dr Desh Bandhu Gupta started Lupin.
1972 - Lupin Laboratories Pvt. Ltd. was incorporated.
1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.
1981 - They started the production of Ethambutol.
1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.
1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).
1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.
1991 - Initiated the production of injectable Cephalosporin at Mandideep.
1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.
1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.
1997 - Three facilities received U.S. FDA approvals.
2000 - Another plant received US FDA approval.
2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.
2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.
2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.
2004 - Started U.S. brands’ business with the launch of Suprax.
2005 - Commenced its generics business in the U.S. Implemented ESOP.
2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.
2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.
2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.
2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.
2010 - Lupin ranked the 5th largest generic player in the U.S.
2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.
2012 - Lupin enters Nifty 50.
2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.
2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.
2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.
2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.
2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd in Osaka.
2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.
View More- NSE Symbol
- LUPIN
- BSE Symbol
- 500257
- ISIN
- INE326A01037
Similar Stocks to Lupin
Popular Stocks
Lupin FAQs
Lupin share price is ₹2,376 As on 07 August, 2026 | 12:55
The Market Cap of Lupin is ₹108661.9 Cr As on 07 August, 2026 | 12:55
The P/E ratio of Lupin is 19.7 As on 07 August, 2026 | 12:55
The PB ratio of Lupin is 4.8 As on 07 August, 2026 | 12:55
The 52 week High & Low of Lupin is ₹2529.5/₹1855 respectively As on 07 August, 2026 | 12:55
For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.
Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.
You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.